This study aimed to explore the ameliorating effects of the platelet
surface glycoprotein IIb/IIIa receptor antagonist
tirofiban on coagulation and fibrinolytic abnormalities in a mouse model of antibody-mediated transfusion-associated
acute lung injury (ALI). This is important because ALI is a major cause of death attributable to the occurrence of adverse
transfusion reactions. No information on a definite diagnosis or pathological mechanism exists, and targeted treatment options are not available. In this study, wild-type male Balb/c mice aged 8 to 10 weeks were randomly divided into the
TRALI model, blank control,
tirofiban intervention, and isotype control groups. After different treatment exposures, the mice were observed for 2 h before being killed, and lung tissue samples were collected. To explore the intervention effect of
tirofiban, the degree of
lung injury was quantified by estimating the
lung wet/dry ratio, rectal temperature, survival rate, total
protein, and
myeloperoxidase and via
hematoxylin-
eosin staining. Furthermore, the coagulation, anticoagulation, and fibrinolysis assays were measured by automatic coagulation instrument and
enzyme-linked
immunosorbent assay kits, and the fluorescence densities of platelets and
fibrin were quantified using immunofluorescence to analyze the effects of
tirofiban on the platelet and
fibrin interactions of
TRALI. Compared with the
TRALI model group, the
lung injury indices in the
tirofiban intervention group decreased significantly, and survival rates also improved. Furthermore, the level of coagulation and fibrinolytic abnormalities were obviously lower than those in the
TRALI model group. In conclusion, our findings suggest that
tirofiban might interfere with
TRALI by inhibiting platelet activation and improving coagulation and fibrinolytic abnormalities.